KEY DETAILS
Foreign Policy Journal reports OpenAI acquired Orchestra Bio to strengthen Rosalind's life sciences capabilities, which it says benefits pharmaceutical groups like Novo Nordisk that already use the platform.
BioSpectrum India reports a Lancet trial published in May 2026 studied 108 adults with moderate-to-severe alcohol use disorder and obesity, and that weekly semaglutide significantly reduced heavy drinking over 26 weeks.
The Markets Daily reports GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 72,715.53%.
SheKnows reports that ZUPREME-1, a Phase 2 trial released in September 2026, found participants lost about 10% of their starting weight after 42 weeks on petrelintide, compared with 1.7% on placebo.
Medical News Today reports a phase 2 petrelintide trial of 485 participants, covered in a study published in September 2026, found participants lost up to 9.8% of body weight over 28 weeks.
OpenAI has acquired Orchestra Bio, and Foreign Policy Journal reports the move is meant to strengthen Rosalind's life sciences capabilities, which it says benefits pharma groups like Novo Nordisk that already use the platform. BioSpectrum India reports that a Lancet trial published in May 2026 found weekly semaglutide significantly reduced heavy drinking over 26 weeks in 108 adults. SheKnows reports that a Phase 2 trial called ZUPREME-1, released in September 2026, found participants on petrelintide lost about 10% of their starting weight after 42 weeks, compared with 1.7% for placebo.
Foreign Policy Journal reports that Novo Nordisk has deepened its reliance on artificial intelligence in drug discovery by integrating OpenAI's Rosalind model into its core research and development operations. The outlet reports the Orchestra Bio acquisition targets key areas of pharmaceutical R&D, including target identification, molecule design, and trial analytics tied to Novo Nordisk's active pipeline. According to Foreign Policy Journal, the deal reinforces Novo Nordisk's broader effort to industrialize discovery work around obesity and cardiometabolic treatments, moving beyond its existing GLP-1 portfolio.
BioSpectrum India's piece on repurposing GLP-1 drugs for alcohol use disorder (AUD) looks at earlier research. The outlet reports that the first randomised, placebo-controlled trial of semaglutide in AUD, published in JAMA Psychiatry in 2025, enrolled 48 adults. It reports that a larger trial, published in the Lancet in May 2026, studied 108 adults with moderate-to-severe AUD and obesity, and found that weekly semaglutide significantly reduced heavy drinking over 26 weeks. BioSpectrum India also notes that one analysis reported GLP-1 drug use was associated with 74% lower odds of AUD compared with non-users.
The Markets Daily published its own figures on October 24, 2026. It reports that GeoVax Labs has a consensus price target of $150.00, suggesting a potential upside of 72,715.53%. By comparison, the outlet reports that Altimmune has a consensus price target of $14.33, suggesting a potential upside of 576.10%. The Markets Daily also reports that GeoVax Labs has a beta of 3.69, suggesting its stock price is 269% more volatile than the S&P 500.
There was also trial coverage of a drug outside the GLP-1 class. According to SheKnows, a study released in September 2026 found that people taking petrelintide lost weight without the type of digestive side effects that can derail GLP-1 treatment. The outlet reports that after 42 weeks on petrelintide, participants had lost about 10% of their starting weight on average, compared with just 1.7% for those on placebo. SheKnows notes the trial, called ZUPREME-1, was a randomized, double-blind, placebo-controlled Phase 2 dose-finding trial funded by Zealand Pharma, the maker of petrelintide, and that petrelintide is not yet approved by the FDA and the results still need to be reproduced in further trials.
Medical News Today's coverage of a study published in September 2026 reports that participants taking petrelintide lost up to 9.8% of their body weight over 28 weeks, with gastrointestinal side effects similar to placebo. The outlet describes petrelintide as an investigational, or experimental, drug. It reports the phase 2 trial involved 485 participants with overweight or obesity and no history of diabetes. According to Medical News Today, researchers found that those taking petrelintide experienced similar gastrointestinal tolerability to the placebo group.
You can read the full details on Novo Nordisk's AI expansion at Foreign Policy Journal, the semaglutide and alcohol research at BioSpectrum India, and the petrelintide trial coverage at SheKnows and Medical News Today. The Markets Daily has the complete figures on GeoVax Labs and Altimmune, for anyone tracking those stocks.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.